OTC: IDRSF - Idorsia Ltd

Altı ay boyunca karlılık: -59.46%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı Idorsia Ltd


Şirket hakkında Idorsia Ltd

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.

daha fazla ayrıntı
Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета chf
Сайт https://www.idorsia.com
Цена ао 1.15
Günlük fiyat değişimi: 0% (1.05)
Haftalık fiyat değişimi: -19.85% (1.31)
Aylık fiyat değişimi: +40% (0.75)
3 ayda fiyat değişimi: +50% (0.7)
Altı ayda fiyat değişimi: -59.46% (2.59)
Yıllık fiyat değişimi: -60.23% (2.64)
3 yılda fiyat değişimi: -94.21% (18.15)
5 yılda fiyat değişimi: -96.18% (27.5)
Yılbaşından bu yana fiyat değişimi: +38.16% (0.76)

Hafife alma

İsim Anlam Seviye
P/S 2.3 6
P/BV -0.3623 0
P/E 0 0
EV/EBITDA -2.69 0
Toplam: 4.38

Yeterlik

İsim Anlam Seviye
ROA, % -59.58 0
ROE, % 30.75 9
Toplam: 3.17

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -2.17 10
Toplam: 9.2

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 539.77 10
karlılık Ebitda, % -44.99 0
karlılık EPS, % -55.07 0
Toplam: 3



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. Jean-Paul Clozel M.D. CEO & Chairman of the Board 956.86k 1955 (70 yıllar)
Dr. Martine Clozel Executive VP & Chief Scientific Officer N/A 1955 (70 yıllar)
Mr. Andrew C. Weiss Senior VP and Head of Investor Relations & Corporate Communications N/A 1968 (57 yıllar)
Mr. Julien Gander L.L.M. Senior VP, Group General Counsel & Company Secretary N/A 1979 (46 yıllar)
Mr. Alexander Khatuntsev Senior VP & Head of Global Human Resources N/A 1978 (47 yıllar)
Dr. Guy Braunstein M.D. Executive VP & Chief Medical Officer N/A 1956 (69 yıllar)
Mr. Olivier Lambert Senior VP & Head of Technical Operations N/A 1966 (59 yıllar)
Mr. Markus A. Riederer Senior VP & Head of Drug Discovery Biology N/A 1962 (63 yıl)
Mr. Alberto Gimona M.D. Executive VP & Head of Global Clinical Development N/A 1960 (65 yıllar)
Mr. Andre C. Muller Executive VP & CFO 1963 (62 yıl)

Adres: Switzerland, Allschwil, Hegenheimermattweg 91 - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.idorsia.com